Cargando…

Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial

BACKGROUND: To explore the effect of abatacept treatment on patient-reported outcomes (PROs) in psoriatic arthritis (PsA). METHODS: Patients with PsA were randomised (1:1) to subcutaneous abatacept 125 mg weekly/placebo for 24 weeks with early escape (EE) to open-label abatacept (week 16). Adjusted...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strand, Vibeke, Alemao, Evo, Lehman, Thomas, Johnsen, Alyssa, Banerjee, Subhashis, Ahmad, Harris A., Mease, Philip J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282264/ https://www.ncbi.nlm.nih.gov/pubmed/30522501 http://dx.doi.org/10.1186/s13075-018-1769-7

Ejemplares similares

Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis
por: Mease, Philip J., et al.
Publicado: (2020)

Improvements in Fatigue in 1536 Patients with Rheumatoid Arthritis and Correlation with Other Treatment Outcomes: A Post Hoc Analysis of Three Randomized Controlled Trials of Abatacept
por: Gossec, Laure, et al.
Publicado: (2017)

Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis
por: Mease, Philip J, et al.
Publicado: (2017)

Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial
por: McInnes, Iain B, et al.
Publicado: (2019)

Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)
por: Fleischmann, Roy, et al.
Publicado: (2019)

Implementation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System in a randomized phase IIb study of abatacept in psoriatic arthritis
por: Østergaard, Mikkel, et al.
Publicado: (2022)

Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives
por: Noisette, Ashley, et al.
Publicado: (2018)

Classification and Outcome Measures for Psoriatic Arthritis
por: Leung, Ying Ying, et al.
Publicado: (2018)

Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry
por: Harrold, Leslie R., et al.
Publicado: (2019)

Abatacept in psoriatic arthritis: Case report and short review
por: Ursini, Francesco, et al.
Publicado: (2013)

Current treatment options for psoriatic arthritis: spotlight on abatacept
por: Ursini, Francesco, et al.
Publicado: (2018)

Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis
por: Szentpetery, Agnes, et al.
Publicado: (2017)

Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept
por: Ahmad, Harris A., et al.
Publicado: (2022)

Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry
por: Choquette, Denis, et al.
Publicado: (2019)

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
por: Mease, Philip J, et al.
Publicado: (2022)

Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set
por: Kalyoncu, Umut, et al.
Publicado: (2016)

Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis
por: Mease, Philip J., et al.
Publicado: (2014)

Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension
por: Eder, Lihi, et al.
Publicado: (2023)

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
por: Coates, Laura C, et al.
Publicado: (2019)

Preface to the psoriatic arthritis supplement
por: Mease, Philip
Publicado: (2020)

Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
por: Strand, Vibeke, et al.
Publicado: (2021)

Infliximab (Remicade) in the treatment of psoriatic arthritis
por: Mease, Philip
Publicado: (2006)

Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination
por: Strand, Vibeke, et al.
Publicado: (2021)

Safety of Abatacept Versus Placebo in Rheumatoid Arthritis: Integrated Data Analysis of Nine Clinical Trials
por: Simon, Teresa A., et al.
Publicado: (2019)

Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond
por: Strand, Vibeke, et al.
Publicado: (2019)

A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice?
por: Harrold, Leslie R., et al.
Publicado: (2017)

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)
por: Gottlieb, Alice B, et al.
Publicado: (2018)

Enthesitis in psoriatic arthritis (Part 3): clinical assessment and management
por: Mease, Philip
Publicado: (2020)

Abatacept in difficult-to-treat juvenile idiopathic arthritis
por: Kuemmerle-Deschner, Jasmin B, et al.
Publicado: (2008)

Real-world burden of comorbidities in US patients with psoriatic arthritis
por: Shah, Kamal, et al.
Publicado: (2017)

Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
por: Mease, Philip J.
Publicado: (2014)

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
por: Ogdie, Alexis, et al.
Publicado: (2023)

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
por: Strand, Vibeke, et al.
Publicado: (2019)

Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis
por: Helliwell, Philip, et al.
Publicado: (2014)

Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J, et al.
Publicado: (2018)

Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol
por: Hazes, Johanna M., et al.
Publicado: (2010)

Pneumocystis jirovecii Pneumonia in a Patient with Rheumatoid Arthritis Treated with Abatacept
por: Ospina, Fabio E., et al.
Publicado: (2014)

Reduced T-cell repertoire restrictions in abatacept-treated rheumatoid arthritis patients
por: Imberti, Luisa, et al.
Publicado: (2015)

Erratum to: Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
por: Mease, Philip J.
Publicado: (2015)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
por: Helliwell, Philip S, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0aqvhu3ts64sioeebhscc5gpnr